ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer

• NASDAQ: $EPIX
• Notified: $6.10
• 07:01 EDT